<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="335720">
  <stage>Registered</stage>
  <submitdate>14/07/2010</submitdate>
  <approvaldate>22/07/2010</approvaldate>
  <actrnumber>ACTRN12610000593033</actrnumber>
  <trial_identification>
    <studytitle>Study of orBec (Registered Trademark (R)) With Prednisone Therapy in the Treatment of Patients With Graft Versus Host Disease (GVHD)</studytitle>
    <scientifictitle>A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Safety and Efficacy of orBec(R) (Oral Beclomethasone 17,21-Dipropionate)in Conjunction With Ten Days of High-Dose Prednisone Therapy in the Treatment of Patients With Gastrointestinal Graft Versus Host Disease (GVHD)</scientifictitle>
    <utrn />
    <trialacronym>SUPPORTS</trialacronym>
    <secondaryid>Study NCT00926575   ClinicalTrials.gov</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Gastrointestinal Graft Versus Host Disease</healthcondition>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>oral beclomethasone 17,21-dipropionate
Two pills (1 milligram) four times a day (8 milligrams) for 50 days. 
Study drug administered in conjunction with standard of care prednisone therapy.</interventions>
    <comparator>Placebo
Two pills (1 milligram lactose monohydrate) four times  a day (8 millligrams) for 50 days.  
Placebo administered in conjunction with standard of care prednisone therapy.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The proportion of subjects with GVHD treatment failure defined as the increased use of prednisone or equivalent intravenous (IV) corticosteroids at doses higher than specified in the protocol or use of any other additional glucocorticoid or the addition of other immunosuppresant medications, in response to uncontrolled signs or symptoms of GVHD.</outcome>
      <timepoint>Day 80</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Cumulative exposure to prednisone assessed by medication records</outcome>
      <timepoint>Day 80</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Survival status via telephone follow-up calls</outcome>
      <timepoint>Day 200</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>*Receipt of allogeneic hematopoietic cell transplant
*Diagnosis of gastrointestinal graft versus host disease (GVHD)
*No gastrointestinal (GI) infection
*Must be able to swallow tablets
*Must be able to read and understand informed consent
*Adequate birth control methods for the duration of the  study</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>*Significant Skin Graft Versus Host Disease 
*Liver Graft Versus Host Disease
*Persistent vomiting
*Human Immunodeficiency Virus (HIV) positive
*Pregnancy/lactation</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by telphone</concealment>
    <sequence>Stratified allocation. Factors such as centre, age gender or previous treatment are used for the stratification.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>13/10/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>166</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>United States of America</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Soligenix, Inc.</primarysponsorname>
    <primarysponsoraddress>29 Emmons Drive
Suite C-10
Princeton, NJ 08540</primarysponsoraddress>
    <primarysponsorcountry>United States of America</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Soligenix, Inc.</fundingname>
      <fundingaddress>29 Emmons Drive
Suite C-10
Princeton, NJ 08540</fundingaddress>
      <fundingcountry>United States of America</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Use of an oral topically-active glucocorticoid with limited side effects will control the gastrointestinal inflammatory process of GVHD and minimize glucocorticoid exposure.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Fred Hutchinson Cancer Research Center Institutional Review Board</ethicname>
      <ethicaddress>1100 Fairview Avenue North
J6-110
Seattle, Washington 98109-1024</ethicaddress>
      <ethicapprovaldate>12/08/2009</ethicapprovaldate>
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>United States of America</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Brian L. Hamilton, MD, PhD</name>
      <address>29 Emmons Drive
Suite C-10
Princeton, NJ 08540</address>
      <phone>+1 609-538-8200</phone>
      <fax />
      <email>bhamilton@soligenix.com</email>
      <country>United States of America</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Brian L. Hamilton, MD, PhD</name>
      <address>29 Emmons Drive
Suite C-10
Princeton, NJ 08540</address>
      <phone>+1 609-538-8200</phone>
      <fax />
      <email>bhamilton@soligenix.com</email>
      <country>United States of America</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Valerie Parker</name>
      <address>29 Emmons Drive
Suite C-10
Princeton, NJ 08540</address>
      <phone>+1 609-538-8200</phone>
      <fax />
      <email>vparker@soligenix.com</email>
      <country>United States of America</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>